GeneDx: Fundamentals Intact Though Q4 Results Pause Near Term Momentum

January 15, 2026

GeneDx: Fundamentals Intact Though Q4 Results Pause Near Term Momentum

GeneDx Holdings Corp. is positioned as a leader in advanced exome and genome diagnostics, leveraging its expanding rare disease dataset.Fourth quarter preliminary results met guidance but did not exceed it

by admin

Biotechnology Stocks

Stock Market

November 12, 2025

Nektar Therapeutics: Balancing The Immune System To Potential Blockbuster Markets

Nektar Therapeutics develops novel immunomodulatory drugs targeting autoimmune diseases and oncology, leveraging its expertise in immune system regulation.Recent Phase 2 results for Atopic Dermatitis met endpoints, validating NKTR's approach and

by admin

Healthcare Stocks

Stock Market

October 27, 2025

GeneDx: A Moment Of Reckoning As Market Awaits Q3 Testing Growth

GeneDx Holdings Corp. is poised for strong Q3 results, driven by expanding exome and genome testing in pediatric and neonatal settings.Key metrics for WGS include test volume growth and reimbursement

by admin

Jonathan Kitchen via Getty Images via Seeking Alpha

Biotechnology Stocks

Stock Market

October 21, 2025

Cidara Therapeutics: A Potential Blockbuster In Flu Prevention

Cidara’s CD388 is a novel flu prophylactic designed for universal prevention of seasonal and pandemic influenza through a single dose, with the potential to be the new standard of care.Phase

by admin

Healthcare Stocks

Stock Market

July 31, 2025

GeneDx Surges Past Q2 Expectations,Sets Up for Strong Year-End Growth

GeneDx delivered a strong Q2 2025, with revenues and earnings beating expectations and full-year guidance raised over 10%.Revenue growth is driven by higher testing volumes, improved reimbursement rates, and a

by admin

Healthcare Stocks

Stock Market

May 20, 2025

GeneDx: Strong Fundamentals Intact As
Market Misreads Test Volume Dip

GeneDx delivered strong Q1 2025 results, beating revenue and EPS estimates, and raised full-year guidance.The test volume dip is attributable to seasonality, adverse weather, and one fewer business day, not

by admin

DNA Screening, Genomics, Prudent Healthcare

Healthcare Stocks

April 28, 2025

GeneDx: Strengthening Leadership In Genomic Diagnostics

GeneDx Holdings Corp. leverages genomic sequencing and data science for early diagnosis and treatment, focusing on pediatric outpatient and neonatal ICU settings.GeneDx will report Q1 2025 earnings on April 30,

by admin

Healthcare Stocks

Stock Market

October 21, 2024

GeneDx Holdings: Stock To Keep Outperforming As Business Momentum Persists

GeneDx Holdings Corp. leverages its genomic and data science expertise to provide precise medical diagnostics, focusing on rare diseases and pediatric exome/genome testing.The company’s second-quarter performance exceeded expectations, driven by

by admin

Healthcare Stocks

Stock Market

July 22, 2024

Healthcare 2024 Second Half Outlook

The S&P Healthcare Index rose 6% in the first half of the year, while the Prudent Healthcare model portfolio gained 25%.While the healthcare index underperformed the broader market, there are

by admin

Biotechnology Stocks

Stock Market

July 9, 2024

Biotech Stocks 2024 Second Half Outlook
Buy Biotechs

Biotech indexes lagged broader market indexes in the first half of 2024, and trade at the same level as in early 2022.Biotech valuations are closely tied to the Fed's interest

by admin

Biotechnology Stocks

Stock Market

June 24, 2024

Nuvalent: Making Precise Progress
In Its Oncology Pipeline

Nuvalent, Inc. is a biotechnology company with precision-targeted treatments using kinase inhibitors for non-small cell lung cancer.NVL-520 targets ROS1-positive cancer and addresses treatment resistance, kinase mutations, and CNS-related adverse events,

by admin

Healthcare Stocks

June 6, 2024

GeneDx Holdings: Mapping A Path To Leadership In Pediatric Genetic Testing

GeneDx Holdings Corp. focuses on delivering precise medical diagnostic outcomes through its genomic expertise and rare disease dataset.Whole Exome Sequencing (WES) and Whole Genome Sequencing (WGS) are key revenue drivers,

by admin

Healthcare Stocks

May 22, 2024

Evolus: Chiseling Away At The Aesthetic Market

by admin

Biotechnology Stocks

May 13, 2024

For Biotech Stocks To Move Higher, This Must Move Lower

Biotech indexes, represented by IBB and XBI, have been facing pressure since March and trading at valuations seen in April 2020.The key factor influencing biotech valuations, discussed below, is expected

by admin

Healthcare Stocks

January 8, 2024

Healthcare Outlook 2024

The healthcare sector had a flat performance in 2023 due to unique issues.Drug price regulation will be an uphill challenge for the sector this year.Defensive healthcare industry groups should do

by admin

Biotechnology Stocks

January 3, 2024

Biotech Bonanza: 2024 Biotech Outlook As The Fed Turns Dovish

The biotech industry experienced a challenging year in 2023 due to a rising 10-year Treasury yield.In 2024, the 10-year yield should favorably support biotech stocks.Promising advancements in weight loss drugs,

by admin

Healthcare Stocks

November 13, 2023

Biotech Stocks Ready To Roar

by admin

Healthcare Stocks

August 14, 2023

Second Half Outlook For Biotech Stocks

Biotech stocks faced challenges in the first half of the year, with the Nasdaq Biotechnology Index losing 3%, compared to strong advances in the broader market.The direction of the 10-year

by admin

Healthcare Stocks

June 13, 2023

Akero Therapeutics: Marching On And Delivering Promising Results

Akero Therapeutics is making strong progress in developing a treatment for NASH, an area of high unmet medical need.The company's lead product candidate has shown promising and highly significant results

by admin

Biotechnology Stocks

Stock Market

May 30, 2023

Iveric bio, Still A 5+% Opportunity

Iveric bio, Inc., focused on developing treatments for retinal diseases, has announced its acquisition by Astellas Pharma Inc.Iveric bio, Inc. stock trades at a discount of over 5% for an

by admin

Biotechnology Stocks

Stock Market

April 24, 2023

Biotech Stocks Second Quarter Outlook

Biotech stocks have been consolidating recently but may be ready to rally higher due to factors such as a declining 10-year yield and growing M&A activity.Biotech deal-making has been increasing,

by admin

Biotechnology Stocks

Stock Market

March 13, 2023

Biotechs Reel From Bank Collapse, But Not All May Be Bad

The collapse of Silicon Valley Bank led to a market-wide selloff and caused significant volatility in biotech and technology stocks.Regulators are expected to take swift action this week to contain

January 23, 2023

Healthcare Outlook 2023

Healthcare significantly outperformed the broader market last year, after two years of underperforming the S&P 500.When the end to restrictive policy is in sight, then the sector is likely to

by admin

Biotechnology Stocks

Stock Market

January 9, 2023

Biotech Bonanza: 2023 Biotech Outlook As The Fed Remains Hawkish

Federal Reserve interest rate policy to again remain the market focus this year and create a chaotic first half.Biotechnology should be favorably positioned relative to the market if the economy

by admin